More Coverage from II31 Jan 2017 08:34
Hi
Sorry being new to this board I thought I could post a link. Trying one more time. If this doesnt work - just go to the II board!
https://
endpts.com/fighting-a-generic-onslaught-novartis-adds-car-t-to-its-growing-list-of-late-stage-blockbusters
And a different article from II yesterday (Bloomberg):
"Novartis AG is pushing ahead with one of its most ambitious cancer therapies, a treatment that the Swiss drugmaker says has blockbuster potential as it extends that technology to a wider pool of tumor-ridden patients.
Europe’s second-biggest drugmaker is planning to test its CAR-T treatments -- which involve extracting immune cells and genetically engineering them to hunt and kill cancer cells before returning them into the patient’s body -- on lethal cancers of the brain, pancreas, colon, ovary and lung. The company has also doubled its investment in manufacturing for these treatments.
The efforts put Novartis in a race with Juno Therapeutics Inc., Kite Pharma Inc. and Bluebird Bio Inc. to master the technology, part of a class of therapies that harness the body’s defense system to attack tumors. Novartis’s initial target is an acute form of leukemia in children, and it expects to seek approval from the U.S. Food and Drug Administration early this year. Analysts estimate the therapy, CTL019, will cross $1 billion in annual sales in five years.
“This could be the most efficacious immune therapy as yet developed, and it’s just early days with this technology,” Jay Bradner, president of the Novartis Institutes for BioMedical Research, said in an interview at the company’s headquarters in Basel, Switzerland."
Sign In
Follow the stocks
